Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

S. Kelderman, B. Heemskerk, H. van Tinteren, R.R.H. van den Brom, G.A.P. Hospers, A.J.M. van den Eertwegh, E.W. Kapiteijn, J.W.B. de Groot, P. Soetekouw, R.L. Jansen, E. Fiets, A.J.S. Furness, A. Renn, M. Krzystanek, Z. Szallasi, P. Lorigan, M.E. Gore, T.N.M. Schumacher, J.B.A.G. Haanen, J.M.G. Larkin & 1 others C.U. Blank

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)449-458
JournalCancer Immunology and Immunotherapy
Volume63
Issue number5
DOIs
Publication statusPublished - 2014

Cite this

Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R. R. H., Hospers, G. A. P., van den Eertwegh, A. J. M., ... Blank, C. U. (2014). Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunology and Immunotherapy, 63(5), 449-458. https://doi.org/10.1007/s00262-014-1528-9
Kelderman, S. ; Heemskerk, B. ; van Tinteren, H. ; van den Brom, R.R.H. ; Hospers, G.A.P. ; van den Eertwegh, A.J.M. ; Kapiteijn, E.W. ; de Groot, J.W.B. ; Soetekouw, P. ; Jansen, R.L. ; Fiets, E. ; Furness, A.J.S. ; Renn, A. ; Krzystanek, M. ; Szallasi, Z. ; Lorigan, P. ; Gore, M.E. ; Schumacher, T.N.M. ; Haanen, J.B.A.G. ; Larkin, J.M.G. ; Blank, C.U. / Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. In: Cancer Immunology and Immunotherapy. 2014 ; Vol. 63, No. 5. pp. 449-458.
@article{6cf5c89a8672468fa6a6924d84003472,
title = "Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma",
author = "S. Kelderman and B. Heemskerk and {van Tinteren}, H. and {van den Brom}, R.R.H. and G.A.P. Hospers and {van den Eertwegh}, A.J.M. and E.W. Kapiteijn and {de Groot}, J.W.B. and P. Soetekouw and R.L. Jansen and E. Fiets and A.J.S. Furness and A. Renn and M. Krzystanek and Z. Szallasi and P. Lorigan and M.E. Gore and T.N.M. Schumacher and J.B.A.G. Haanen and J.M.G. Larkin and C.U. Blank",
year = "2014",
doi = "10.1007/s00262-014-1528-9",
language = "Undefined/Unknown",
volume = "63",
pages = "449--458",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "5",

}

Kelderman, S, Heemskerk, B, van Tinteren, H, van den Brom, RRH, Hospers, GAP, van den Eertwegh, AJM, Kapiteijn, EW, de Groot, JWB, Soetekouw, P, Jansen, RL, Fiets, E, Furness, AJS, Renn, A, Krzystanek, M, Szallasi, Z, Lorigan, P, Gore, ME, Schumacher, TNM, Haanen, JBAG, Larkin, JMG & Blank, CU 2014, 'Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma' Cancer Immunology and Immunotherapy, vol. 63, no. 5, pp. 449-458. https://doi.org/10.1007/s00262-014-1528-9

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. / Kelderman, S.; Heemskerk, B.; van Tinteren, H.; van den Brom, R.R.H.; Hospers, G.A.P.; van den Eertwegh, A.J.M.; Kapiteijn, E.W.; de Groot, J.W.B.; Soetekouw, P.; Jansen, R.L.; Fiets, E.; Furness, A.J.S.; Renn, A.; Krzystanek, M.; Szallasi, Z.; Lorigan, P.; Gore, M.E.; Schumacher, T.N.M.; Haanen, J.B.A.G.; Larkin, J.M.G.; Blank, C.U.

In: Cancer Immunology and Immunotherapy, Vol. 63, No. 5, 2014, p. 449-458.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

AU - Kelderman, S.

AU - Heemskerk, B.

AU - van Tinteren, H.

AU - van den Brom, R.R.H.

AU - Hospers, G.A.P.

AU - van den Eertwegh, A.J.M.

AU - Kapiteijn, E.W.

AU - de Groot, J.W.B.

AU - Soetekouw, P.

AU - Jansen, R.L.

AU - Fiets, E.

AU - Furness, A.J.S.

AU - Renn, A.

AU - Krzystanek, M.

AU - Szallasi, Z.

AU - Lorigan, P.

AU - Gore, M.E.

AU - Schumacher, T.N.M.

AU - Haanen, J.B.A.G.

AU - Larkin, J.M.G.

AU - Blank, C.U.

PY - 2014

Y1 - 2014

U2 - 10.1007/s00262-014-1528-9

DO - 10.1007/s00262-014-1528-9

M3 - Article

VL - 63

SP - 449

EP - 458

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 5

ER -